Curr Stem Cell Res Ther. 2020 Mar 16. doi: 10.2174/1574888X15666200316164051. [Epub ahead of print]

Human Mesenchymal Stem Cells for Spinal Cord Injury.

Anbiyaiee A¹, Khoshnam SE², Farzaneh M³, Alishahi M⁴.

Abstract

Spinal cord injury (SCI) as a devastating and life-altering neurological disorder is one of the most serious health issues. Currently, the management of acute SCI includes pharmacotherapy and surgical decompression. Both approaches have been assumed to have adverse physiological effects for SCI patients. Therefore, novel therapeutic targets for the management of SCI are urgently required for moving experimental strategies forward cell-based therapies. Multipotent Stem stem cells as a novel strategy for the treatment of tissue injury may provide an effective therapeutic option against many neurological disorders. Mesenchymal stem cells (MSCs) or multipotent stromal cells Stem cells typically can divide or self-renew and generate various cell types, and also have the potential to develop into many different types of cells. Mesenchymal. stem cells (MSCs) or multipotent stromal cells as one of the most promising types of stem cells These cells are often isolated from bone marrow (BM-MSCs), adipose tissues (AD-MSCs), umbilical cord blood (UCB-MSCs), and placenta (PMSCs). MSCs have the remarkable potential for the development of regenerative therapies in animal models and humans with SCI. Herein, we summarize the therapeutic potential of human MSCs in the treatment of SCI.